Cetuximab did not improve PFS, OS in combination regimen for metastatic colorectal cancer

Harris, Jason; Southall, Jennifer
October 2010
Hem/Onc Today;10/25/2010, Vol. 11 Issue 20, p17
The article discusses research being conducted on the effectiveness of cetuximab for treating metastatic colorectal cancer, which references a study by Kjell Magne Tveit and colleagues that was presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy from October 8-12, 2010.


Related Articles

  • Cetuximab detrimental in KRAS-mutant mCRC.  // Reactions Weekly;Aug2015, Vol. 1562 Issue 1, p8 

    The article discusses research published in the July 7, 2015 issue of "Anticancer Research" that provided evidence of the detrimental effects of cetuximab in patients with metastatic colorectal cancer with KRAS codon 12 mutations.

  • Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer. Krawczyk, Paweł Adam; Kowalski, Dariusz M. // Contemporary Oncology / Wspolczesna Onkologia;2014, Vol. 18 Issue 1, p7 

    Efficacy of monoclonal anti-EGFR antibodies (cetuximab, panitumumab) used in combination with chemotherapy or alone has been demonstrated in clinical trials of patients with mCRC. Both drugs block signaling EGFR pathway in malignant cells (blocking ligand binding and EGFR dimerization)....

  • Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. Petrelli, Fausto; Borgonovo, Karen; Cabiddu, Mary; Ghilardi, Mara; Barni, Sandro // International Journal of Colorectal Disease;Jul2011, Vol. 26 Issue 7, p823 

    Background: Anti-epidermal growth factor receptor monoclonal antibodies (panitumumab [P] and cetuximab [C]) are approved and effective only in KRAS wild-type patients with advanced colorectal cancer. The purpose of our meta-analysis is to evaluate the real effects of C and P in KRAS wild-type...

  • EGFR-targeted therapy in metastatic colorectal cancer. Kennecke, Hagen // Oncology Exchange;May2012, Vol. 11 Issue 2, pe.22 

    Numerous Phase III studies have documented the benefit of panitumumab and cetuximab in first-, second-, and third-line treatment of nonmutated/ wild-type (WT) KRAS metastatic colorectal cancer (mCRC). Doublet 5-fluorouracil-based chemotherapy with irinotecan or oxaliplatin (FOLFIRI or FOLFOX)...

  • Prevalence of KRAS mutations in metastatic colorectal cancer: A retrospective observational study from India. Veldore, V. H.; Rao, M. R.; Prabhudesai, S. A.; Tejaswi, R.; Kakara, S.; Pattanayak, S.; Krishnamoorthy, N.; Tejaswini, B. N.; Hazarika, D.; Gangoli, A.; Rahman, S. M.; Dixit, J.; Naik, R.; Diwakar, R. B.; Satheesh, C. T.; Shashidhara, H. P.; Patil, S.; Gopinath, K. S.; Kumar, B. S. Ajai; Kumar, B S // Indian Journal of Cancer;Oct-Dec2014, Vol. 51 Issue 4, p531 

    Background: One of the genetic alterations implicated in tumor progression in colorectal cancers (CRCs) are abnormalities in Kristen Rat Sarcoma (KRAS) gene. Evaluation of KRAS mutation status is an important prognostic factor and has predictive value in deciding first line therapy...

  • Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis. Bouchahda, M.; Macarulla, T.; LIedo, G.; Lévi, F.; Elez, M.; Paule, B.; Karaboué, A.; Artru, P.; Tabernero, J.; Machover, D.; Innominato, P.; Goldschmidt, E.; Bonnet, D.; Ducreux, M.; Castagne, V.; Guimbaud, R. // Medical Oncology;Dec2011, Vol. 28, p253 

    Cetuximab was approved using a weekly schedule, alone or in combination with chemotherapy (CT). However, many CT regimens in metastatic colorectal cancer (CRC) are delivered every 2 weeks (q2wks). Preliminary data suggested that a simplified schedule using cetuximab q2wks, 500 mg/m² would be...

  • A Two- year review of Colorectal Cancer at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. Zemenfes, D.; Kotisso, B. // East & Central African Journal of Surgery;Jul/Aug2015, Vol. 20 Issue 2, p10 

    Background: Colorectal Cancer is the third most common cause of admission and death in the West; and till recently it was thought to be an uncommon disease in Africa and Asia. Although data from Ethiopia is unavailable, a recent report from Global cancer statistics center shows an increasing...

  • P53 Linked to Inflammation. Breindl, Anette // BioWorld Today;5/20/2013, Vol. 24 Issue 96, Special section p2 

    The article discusses a research on inflammation-associated colon cancer, in reference to a study conducted by researchers from the Israeli Weizmann Institute of Science and published in the May 13, 2013 issue of "Cancer Cell."

  • Association of epigenetic alteration in PTEN gene with colorectal cancer progression among Indian population. Rizvi, M.; Ali, Asgar; Mehdi, Syed; Saluja, Sundeep; Mishra, Pramod // International Journal of Colorectal Disease;Feb2013, Vol. 28 Issue 2, p283 

    A letter to the editor about the association of epigenetic alteration in PTEN gene with colorectal cancer progression is presented.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics